



December 6, 2017

Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

BURLINGTON, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial Operations, will participate in a fireside chat at the BMO Capital Markets Prescriptions for Success Healthcare Conference in New York City on Thursday, December 14, 2017 at 8:30 am ET. To access the live webcast and subsequent archived recording of the presentation, please visit the Flexion website at <http://ir.flexiontherapeutics.com/>.

About Flexion Therapeutics

Flexion Therapeutics (Nasdaq:FLXN) is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Flexion was named one of the *Boston Business Journal's* 2017 Best Places to Work and one of the Top Places to Work in Massachusetts by *The Boston Globe*.

Corporate Contact:

Scott Young
Sr. Director, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
syoung@flexiontherapeutics.com